EUVIMEDEUVIMED entdecken
CrossrefInfokarte

TRENDS OF MORBIDITY AND MORTALITY IN POLAND FROM MALIGNANT TUMORS OF THE NASAL CAVITY AND MIDDLE EAR (ICD-C30)

Patrycja Zaborska, Jurek Olszewski

Journal of Hearing Science · 2026-05-29 · 16 (1) · 23-29

DOI: 10.17430/jhs/219154 ↗
AbstractBibliografische Angaben

Abstract

Introduction The aim of the study was to compare the incidence and mortality in Poland from malignant tumors of the nasal cavity and middle ear (ICD-C30) with other head and neck cancers over the years 2000 to 2022. Material and methods Incidence and death due to malignant tumors in Poland was based on data from the Polish National Cancer Registry (KRN) over the years 2000, 2005, 2010, 2015, 2020, and 2022. As a benchmark, we compare worldwide rates from the latest GLOBOCAN estimates developed by the International Agency for Research on Cancer (IARC) and distributed as Cancer Today in the Global Cancer Observatory. Results Based on figures from the Polish National Cancer Registry for the years 2000 and 2022, the incidence of malignant tumors of the nasal cavity and middle ear in the country has increased by 18.1%, with an increase of 15.5% in women and 20.4% in men. In terms of deaths from such tumors, however, the same source showed an overall increase of 33.3%, which comprised 56.2% for women and 20.7% for men. Conclusions A malignant tumor of the nasal cavity and middle ear (ICD-C30) is the 20th most common cancer of the head and neck. The Polish National Cancer Registry from 2022 shows that ICD-C30 is the 19th most common cancer of the head and neck in terms of deaths, comparable with malignant tumor of the gums (ICD-C03). In terms of incidence, the most common head and neck cancer based on the same source is thyroid cancer (ICD-C73), and in terms of deaths, laryngeal cancer (ICD-C32).

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →